This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...
The study examines the global policy landscape for invasive fungal infections, identifies key policy gaps, and underscores the need for stronger policy...
The event aims at connecting the global community of arbitration practitioners, both in person and virtually, fostering rich academic discussions and...
CRA is a proud sponsor of the the epicenter of the specialty pharmacy industry event. Becky Davis presents the session titled “GLP-1s: Riding the Wave of...
